Celltrion’s Corona 19 antibody treatment’Rekirona’. It began to be supplied to medical institutions nationwide from the 17th. Celltrion provided
It was estimated that 151 vials were supplied to four medical institutions on the first day of supplying the antibody treatment drug’Rekironaju’ for a new Korean coronavirus infection (COVID-19, Corona 19).
The Central Defense Countermeasure Headquarters (Bang Dae-bon) announced that the supply status of Celltrion’s 960 mg (regdanbimab) of Rekkirona juice as of 0 o’clock on the 18th was identified.
Rekironaju began to be supplied to medical institutions nationwide from the 17th, and among corona19 confirmed patients from the Ministry of Food and Drug Safety, patients within 7 days from the onset of symptoms, among patients who do not need oxygen therapy, are over 60 years of age or with underlying diseases, accompanied by pneumonia. Conditional permission has been obtained for administration to patients.
Daebon Bang explained that the case of’remdesivir’, which was specially imported as a treatment for Corona 19, was currently administered to 4522 patients in 121 hospitals.
In the case of blood system medicine, 38 cases were approved by the Ministry of Food and Drug Safety for treatment other than clinical trial purposes.
Meanwhile, in the case of the Corona 19 virus, which began pre-sale through the National Pathogen Resource Bank on the 8th of this month, 832 cases have been sold to a total of 208 institutions so far. Among them, a total of 5 weeks for the UK mutant virus and a total of 5 weeks for the South African mutant virus. A total of 537 nucleic acids were sold.
The recent emergence and spread of a mutant virus is emerging as an important variable that will determine the future corona19 epidemic. Pfizer of the U.S. announced on the 17th (local time) that its corona19 vaccine could reduce the level of antibody protection against the South African mutant virus by about two-thirds, which may reduce the preventive effect. .
Yang Dong-gyo, head of the Resource Management Division of the Corona 19 Vaccination Response Promotion Team, said, “I know that each manufacturer has initiated a vaccine development study to respond to the mutant virus.” “We plan to respond to necessary areas while continuously monitoring the vaccine development process.” .
As of the 18th, there were a total of 99 confirmed cases of mutant virus in Korea, including 80 mutant infections from the UK, 13 mutant infections from South Africa, and 6 mutant infections from Brazil.